By Fineline Cube 
US-based generics firm Viatris Inc. (NASDAQ: VTRS) reported Q2 2025 financial results, showing a 7% year-on-year decrease in global revenues to USD 3.58 billion. This decline was driven by challenges including an FDA warning letter and import alert related to its manufacturing facility in Indore, India.
Regional Performance
- Greater China: The only region with growth, achieving a 9% sales increase to USD 588.9 million.
- Developed Markets: Sales fell by 11% to USD 2.12 billion.
- Emerging Markets: Declined by 3% to USD 555.1 million.
- JANZ Region: Experienced a 14% decrease to USD 305.7 million.
Impact of FDA Warning
The FDA warning letter and import alert issued in December 2024 had a significant financial impact, resulting in a USD 160 million loss in Q2 and USD 300 million over the first half of 2025. CEO Scott Andrew Smith indicated during the earnings call that the company is approximately 80% remediated in its Indore facility and plans to meet with the FDA soon to resolve the remaining issues.
China Market Insights
Chief Commercial Officer Corinne M. Le Goff attributed the growth in Greater China to the company’s diversified commercial model, which includes e-commerce, retail, and private hospitals. She noted that about 95% of Viatris’ portfolio is included in the national Volume-Based Procurement (VBP) program, which helps reduce market uncertainty. Patients continue to show consistent demand for Viatris’ well-established brands. The company expects China’s growth to moderate to low- to mid-single digits for the remainder of the year.-Fineline Info & Tech